The Department of Health in Abu Dhabi and global pharmaceutical provider Novartis have partnered to develop solutions in multiple medical fields, placing emphasis on advancing clinical genomics through the generation of real-world evidence and radioligand therapy for cancer patients.
The collaboration aims to elevate genomics research in cancer treatments, cardiovascular disease, and neuroscience and to enhance awareness and understanding of radioligand therapy, a precision-based treatment for advanced cancers.
The partnership will also support local and regional health needs, including the Emirati Genome Program, and will contribute to transforming the Health Technology Assessment.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.